Skip to main content

Table 1 General characteristics of the whole group and the two subgroups according to the presence of an ultrasound goiter

From: Systematic thyroid screening in myotonic dystrophy: link between thyroid volume and insulin resistance

Patient characteristics Whole group UsGoiter UsNonGoiter p-value
Number of patients (N; %) N = 115 N = 44 (38.3) N = 71 (61.7)  
Age (mean ± SD, years) 45.1 ± 12.2 46.6 ± 9.7 44.1 ± 13.5 .26
Sex
 Female ♀ (n/N; %) 71/115 (61.7) 28/44 (63.6) 43/71 (60.6) .86
 Minimum of one child (n/N; %) 45/71 (63.4) 18/28 (66.7) 27/43 (62.8) .74
Smoking habits (n/N; %) 45/105 (42.9) 17/44 (38.6) 28/60 (46.7) .36
Clinical forms (n/N; %)
 Congenital form 5/115 (4.3) 2/44 (4.5) 3/71 (4.2) .88
 Infantile form 14/115 (12.2) 5/44 (11.4) 9/71 (12.7) .76
 Juvenile form 21/115 (18.3) 13/44 (29.5) 8/71 (11.3) .08
 Adult form 57/115 (49.6) 31/44 (70.5) 26/71 (36.6) .09
 Late onset form 18/115 (15.6) 6/44 (13.6) 12/71 (16.9) .10
Weight (mean ± SD, kg) 72.5 ± 18.0 78.2 ± 18.6 69.6 ± 16.8 .011
BMI (mean ± SD, kg/m2) 26.4 ± 6.5 28.1 ± 7.1 25.0 ± 5.9 .013
Number of CTG repeats (median (IQR)) 500 (260–850) 500 (300–850) 515 (254–785) .90
CPK (median (IQR); IU/L) 204 (108–293) 217 (106–312) 186 (112–278) .56
Obstructive sleep apnea syndrome (n/N; %) 65/115 (56.5) 27/44 (61.4) 38/71 (53.5) .55
 CPAP (n/N; %) 40/65 (61.5) 16/27 (35.6) 24/38 (33.8) .89
Pacemaker or defibrillator (CIED) (n/N; %) 28/115 (24.3) 13/44 (29.5) 15/71 (21.1) .34
  1. Abbreviations: Us Ultrasound, SD standard deviation, IQR Interquartile, BMI Body mass index, CPK Creatinine phosphokinase, CPAP Continuous positive airway pressure, CIED Cardiovascular implantable electric device, CTG cytosine-thymidine-Guanine
  2. Clinical forms: (1) congenital form: neonatal (mild to severe) hypotonia, respiratory distress, sucking or swallowing difficulties, or skeletal deformities detected at birth or during the first month of life; (2) infantile form: clinical onset from one month to 10 years; (3) juvenile form: onset at 11–20 years; (4) adult form: onset at 21–40 years; (5) late-onset form: onset after 40 years